AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology

Journal of the American College of Cardiology

Volumn 38, Issue 5, 2001, Pages 1581-1583

  Smith Jr , Sidney C ^b   Blair, Steven N ^b   Bonow, Robert O ^b   Brass, Lawrence M ^b   Cerqueira, Manuel D ^b   Dracup, Kathleen ^b   Fuster, Valentin ^b   Gotto, Antonio ^b   Grundy, Scott M ^b   Miller, Nancy Houston ^b   Jacobs, Alice ^b   Jones, Daniel ^b   Krauss, Ronald M ^b   Mosca, Lori ^b   Ockene, Ira ^b   Pasternak, Richard C ^b   Pearson, Thomas ^b   Pfeffer, Marc A ^b   Starke, Rodman D ^b   Taubert, Kathryn A ^b  

^a AMERICAN COLLEGE OF CARDIOLOGY   (United States)

^b NONE

Author keywords

AHA Scientific Statements; Atherosclerosis; Prevention; Risk factors

Indexed keywords

CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES;

EID: 0035500039     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01682-5     Document Type: Article

References (33)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
2. American Diabetes Association clinical practice recommendations 2001
3. Secondary prevention of vascular disease by prolonged antiplatelet treatment
4. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
5. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
6. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
7. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction
8. A case-management system for coronary risk factor modification after acute myocardial infarction
9. Exercise standards for testing and training: A statement for healthcare professionals from the American Heart Association
10. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP)
11. Guidelines for the management of patients with chronic stable angina
12. Diabetes mellitus: A major risk factor for cardiovascular disease: A joint editorial by the American Diabetes Association, the National Heart, Lung, and Blood Institute, the Juvenile Diabetes Foundation International, the National Institute of Diabetes and Digestive and Kidney Diseases, and the American Heart Association
13. Various intensities of leisure time physical activity in patients with coronary artery disease: Effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions
14. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
15. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group
16. Cost-effectiveness of a smoking cessation program after myocardial infarction
17. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
18. Timolol-induced reduction in mortality and reinfarction in patents surviving acute myocardial infarction
19. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
20. Optimal risk factor management in the patient after coronary revascularization: A statement for healthcare professionals from an American Heart Association writing group
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
22. Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient
23. ACE inhibition in acute myocardial infarction
24. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
25. The continuation of the Prevention of Events with Angiotensin-Converting Enzyme inhibition (PEACE) trial
26. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: The Stanford Coronary Risk Intervention Project (SCRIP)
27. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
28. The antiplatelet effects of ticlopidine and clopidogrel
29. The sixth report of the joint national committee on detection, evaluation, and treatment of high blood pressure (JNC VI)
30. Preventing heart attack and death in patients with coronary disease
31. Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction
32. The effect of warfarin on mortality and reinfarction after myocardial infarction
33. Beta-blockers after myocardial infarction: Influence of first-year clinical course on long-term effectiveness